Beta Bionics Reports Q1 2026 Financial Results and Raises Guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 22 2026
0mins
Should l Buy BBNX?
Source: NASDAQ.COM
- Significant Sales Growth: In Q1 2026, Beta Bionics reported net sales of $27.60 million, a 57% increase from $17.60 million in Q1 2025, indicating strong performance in the medical device market despite a decline in new patient starts.
- Channel Contribution Analysis: Of the net sales, the durable medical equipment channel contributed $16.90 million, while the pharmacy benefit plan channel accounted for $10.70 million, demonstrating progress in diversifying revenue sources.
- Improved Financial Losses: The net loss for the quarter was $21.90 million, or 79% of sales, which is an improvement from a loss of $28.70 million (162% of sales) in the same period last year, reflecting efforts in cost control.
- Optimistic Future Outlook: The company estimates total revenues for 2026 to be between $131 million and $136 million, up from previous estimates of $130 million to $135 million, indicating confidence in market demand, while the reimbursement rate for new patient starts is expected to rise to 37%-39%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BBNX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BBNX
Wall Street analysts forecast BBNX stock price to rise
9 Analyst Rating
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 10.200
Low
17.00
Averages
27.11
High
40.00
Current: 10.200
Low
17.00
Averages
27.11
High
40.00
About BBNX
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Beta Bionics Reports Q1 2026 Financial Results and Raises Guidance
- Significant Sales Growth: In Q1 2026, Beta Bionics reported net sales of $27.60 million, a 57% increase from $17.60 million in Q1 2025, indicating strong performance in the medical device market despite a decline in new patient starts.
- Channel Contribution Analysis: Of the net sales, the durable medical equipment channel contributed $16.90 million, while the pharmacy benefit plan channel accounted for $10.70 million, demonstrating progress in diversifying revenue sources.
- Improved Financial Losses: The net loss for the quarter was $21.90 million, or 79% of sales, which is an improvement from a loss of $28.70 million (162% of sales) in the same period last year, reflecting efforts in cost control.
- Optimistic Future Outlook: The company estimates total revenues for 2026 to be between $131 million and $136 million, up from previous estimates of $130 million to $135 million, indicating confidence in market demand, while the reimbursement rate for new patient starts is expected to rise to 37%-39%.
See More
Beta Bionics Q1 2026 Earnings Highlights
- Significant Sales Growth: Beta Bionics reported net sales of $27.6 million in Q1 2026, reflecting a 57% year-over-year increase, indicating substantial progress in driving adoption of the iLet and expanding pharmacy channel access.
- Margin Expansion: The gross margin for Q1 reached 59.5%, an increase of 864 basis points year-over-year, showcasing the company's success in production efficiency and cost management, with expectations for further margin expansion ahead.
- Upward Revenue Guidance: The company raised its total revenue guidance for 2026 to between $131 million and $136 million, up from the previous range of $130 million to $135 million, demonstrating management's confidence in market demand.
- Improved Patient Start Ratio: The percentage of new patient starts reimbursed through the pharmacy channel increased to 37% to 39%, compared to the prior guidance of 36% to 38%, indicating a steady improvement in the company's penetration in the pharmacy channel.
See More
Beta Bionics BBNX Q1 2026 Earnings Transcript
See More
Beta Bionics Q1 Earnings Beat Expectations
- Strong Earnings Report: Beta Bionics reported a Q1 GAAP EPS of -$0.49, beating expectations by $0.01, indicating a slight improvement in financial performance despite remaining in the red.
- Significant Revenue Growth: The company achieved Q1 revenue of $27.6 million, a 56.8% year-over-year increase, surpassing market expectations by $630,000, reflecting robust product demand and expanding market share.
- 2026 Financial Guidance: Beta Bionics has raised its 2026 total revenue guidance to approximately $131 million to $136 million, up from the previous estimate, demonstrating confidence in future growth prospects.
- Increased Patient Reimbursement: The estimated reimbursement rate for new patients through the PBP channel is projected to rise to 37% to 39%, up from the previous 36% to 38%, indicating enhanced competitiveness in the healthcare insurance sector.
See More
Beta Bionics Shares Surge 10.3% Amid Optimism for Q1 Results
- Stock Performance: Beta Bionics, Inc. (BBNX) rallied 10.3% in the last trading session to close at $13.02, with notable trading volume exceeding typical levels, indicating strong investor interest and reflecting optimism about the company's future performance.
- Financial Expectations: The company is set to release its Q1 2026 financial results, with an anticipated loss of $0.53 per share, representing a year-over-year decline of 1.9%, while revenues are expected to reach $27.75 million, up 57.3% from the previous year, showcasing robust sales growth potential.
- Sales Channel Growth: In the previous quarter, Beta Bionics reported a 57% year-over-year revenue increase, driven by a staggering 295% surge in net sales from the Pharmacy Benefit Plan (PBP) channel, indicating rapidly rising market demand in the medical devices sector.
- Market Attention: Although the EPS estimates for BBNX have remained unchanged over the past 30 days, investors should monitor future earnings estimate revisions closely, as these are closely correlated with short-term stock price movements; the current Zacks Rank is 3 (Hold), reflecting a cautious market outlook on its future performance.
See More
Beta Bionics Launches Bionic Insights™, Revolutionizing Diabetes Management
- Innovative Reporting: Beta Bionics has launched Bionic Insights™, a new feature within its Bionic Reports designed to assist healthcare providers in making more personalized treatment recommendations for diabetes patients, thereby enhancing treatment outcomes and patient satisfaction.
- Transformative Data Interpretation: This feature goes beyond traditional glucose reporting by surfacing clinically relevant indicators, patient activities, and system events, enabling clinicians to gain clearer insights into patient data and optimize treatment plans.
- Success and Opportunity Identification: Bionic Insights organizes information into areas of success and opportunity, allowing physicians to quickly identify factors influencing glucose outcomes, reducing time spent on raw data interpretation and increasing meaningful patient interactions.
- Mission-Driven Innovation: Beta Bionics is committed to simplifying diabetes management through innovation, and the launch of Bionic Insights marks a significant step in improving patient quality of life and treatment effectiveness.
See More
Beta Bionics Reports Q1 2026 Financial Results and Raises Guidance
- Significant Sales Growth: In Q1 2026, Beta Bionics reported net sales of $27.60 million, a 57% increase from $17.60 million in Q1 2025, indicating strong performance in the medical device market despite a decline in new patient starts.
- Channel Contribution Analysis: Of the net sales, the durable medical equipment channel contributed $16.90 million, while the pharmacy benefit plan channel accounted for $10.70 million, demonstrating progress in diversifying revenue sources.
- Improved Financial Losses: The net loss for the quarter was $21.90 million, or 79% of sales, which is an improvement from a loss of $28.70 million (162% of sales) in the same period last year, reflecting efforts in cost control.
- Optimistic Future Outlook: The company estimates total revenues for 2026 to be between $131 million and $136 million, up from previous estimates of $130 million to $135 million, indicating confidence in market demand, while the reimbursement rate for new patient starts is expected to rise to 37%-39%.
See More
Beta Bionics Q1 2026 Earnings Highlights
- Significant Sales Growth: Beta Bionics reported net sales of $27.6 million in Q1 2026, reflecting a 57% year-over-year increase, indicating substantial progress in driving adoption of the iLet and expanding pharmacy channel access.
- Margin Expansion: The gross margin for Q1 reached 59.5%, an increase of 864 basis points year-over-year, showcasing the company's success in production efficiency and cost management, with expectations for further margin expansion ahead.
- Upward Revenue Guidance: The company raised its total revenue guidance for 2026 to between $131 million and $136 million, up from the previous range of $130 million to $135 million, demonstrating management's confidence in market demand.
- Improved Patient Start Ratio: The percentage of new patient starts reimbursed through the pharmacy channel increased to 37% to 39%, compared to the prior guidance of 36% to 38%, indicating a steady improvement in the company's penetration in the pharmacy channel.
See More
Beta Bionics BBNX Q1 2026 Earnings Transcript
See More
Beta Bionics Q1 Earnings Beat Expectations
- Strong Earnings Report: Beta Bionics reported a Q1 GAAP EPS of -$0.49, beating expectations by $0.01, indicating a slight improvement in financial performance despite remaining in the red.
- Significant Revenue Growth: The company achieved Q1 revenue of $27.6 million, a 56.8% year-over-year increase, surpassing market expectations by $630,000, reflecting robust product demand and expanding market share.
- 2026 Financial Guidance: Beta Bionics has raised its 2026 total revenue guidance to approximately $131 million to $136 million, up from the previous estimate, demonstrating confidence in future growth prospects.
- Increased Patient Reimbursement: The estimated reimbursement rate for new patients through the PBP channel is projected to rise to 37% to 39%, up from the previous 36% to 38%, indicating enhanced competitiveness in the healthcare insurance sector.
See More
Beta Bionics Shares Surge 10.3% Amid Optimism for Q1 Results
- Stock Performance: Beta Bionics, Inc. (BBNX) rallied 10.3% in the last trading session to close at $13.02, with notable trading volume exceeding typical levels, indicating strong investor interest and reflecting optimism about the company's future performance.
- Financial Expectations: The company is set to release its Q1 2026 financial results, with an anticipated loss of $0.53 per share, representing a year-over-year decline of 1.9%, while revenues are expected to reach $27.75 million, up 57.3% from the previous year, showcasing robust sales growth potential.
- Sales Channel Growth: In the previous quarter, Beta Bionics reported a 57% year-over-year revenue increase, driven by a staggering 295% surge in net sales from the Pharmacy Benefit Plan (PBP) channel, indicating rapidly rising market demand in the medical devices sector.
- Market Attention: Although the EPS estimates for BBNX have remained unchanged over the past 30 days, investors should monitor future earnings estimate revisions closely, as these are closely correlated with short-term stock price movements; the current Zacks Rank is 3 (Hold), reflecting a cautious market outlook on its future performance.
See More
Beta Bionics Launches Bionic Insights™, Revolutionizing Diabetes Management
- Innovative Reporting: Beta Bionics has launched Bionic Insights™, a new feature within its Bionic Reports designed to assist healthcare providers in making more personalized treatment recommendations for diabetes patients, thereby enhancing treatment outcomes and patient satisfaction.
- Transformative Data Interpretation: This feature goes beyond traditional glucose reporting by surfacing clinically relevant indicators, patient activities, and system events, enabling clinicians to gain clearer insights into patient data and optimize treatment plans.
- Success and Opportunity Identification: Bionic Insights organizes information into areas of success and opportunity, allowing physicians to quickly identify factors influencing glucose outcomes, reducing time spent on raw data interpretation and increasing meaningful patient interactions.
- Mission-Driven Innovation: Beta Bionics is committed to simplifying diabetes management through innovation, and the launch of Bionic Insights marks a significant step in improving patient quality of life and treatment effectiveness.
See More
